IL292696B2 - Methods for treating and/or preventing serious adverse cardiovascular events with a combination of a BET bromodomain inhibitor and a sodium-dependent glucose transporter 2 inhibitor - Google Patents
Methods for treating and/or preventing serious adverse cardiovascular events with a combination of a BET bromodomain inhibitor and a sodium-dependent glucose transporter 2 inhibitorInfo
- Publication number
- IL292696B2 IL292696B2 IL292696A IL29269622A IL292696B2 IL 292696 B2 IL292696 B2 IL 292696B2 IL 292696 A IL292696 A IL 292696A IL 29269622 A IL29269622 A IL 29269622A IL 292696 B2 IL292696 B2 IL 292696B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- subject
- sglt2
- inhibitor
- mace
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL292696A IL292696A (en) | 2022-07-01 |
| IL292696B1 IL292696B1 (en) | 2026-01-01 |
| IL292696B2 true IL292696B2 (en) | 2026-05-01 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292696A IL292696B2 (en) | 2019-11-05 | 2020-11-04 | Methods for treating and/or preventing serious adverse cardiovascular events with a combination of a BET bromodomain inhibitor and a sodium-dependent glucose transporter 2 inhibitor |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) * | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2022155303A1 (en) * | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025226A2 (en) * | 2013-08-21 | 2015-02-26 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| WO2016147053A1 (en) * | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| KR20160043118A (ko) | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| MA43037A (fr) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
| JP6849804B2 (ja) | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| KR20220124736A (ko) | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
-
2020
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 IL IL292696A patent/IL292696B2/en unknown
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025226A2 (en) * | 2013-08-21 | 2015-02-26 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| WO2016147053A1 (en) * | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
Non-Patent Citations (4)
| Title |
|---|
| CLEGG LINDSAY E, HEERSPINK HIDDO, PENLAND ROBERT C, TANG WEIFENG, BOULTON DAVID W, BACHINA SRINIVAS, FOX ROBERT D, FENICI PETER, T, REDUCTION OF CARDIOVASCULAR RISK AND IMPROVED ESTIMATED GLOMERULAR FILTRATION RATE BY SGLT2 INHIBITORS, INCLUDING DAPAGLIFLOZIN, IS CONSISTENT ACROSS THE CLASS: AN ANALYSIS OF THE PLACEBO ARM OFEXSCEL, 28 February 2019 (2019-02-28) * |
| GHOSH GOPAL C., BHADRA RAJARSHI, GHOSH RAKTIM K., BANERJEE KINJAL, GUPTA ANJAN:, RVX 208: A NOVEL BETPROTEIN INHIBITOR, ROLE AS AN INDUCER OFAPO A-I/HDL AND BEYOND, 14 July 2017 (2017-07-14) * |
| PRAKASH DEEDWANIA , TUSHAR ACHARYA:, CARDIOVASCULAR PROTECTION WITH ANTI-HYPERGLYCEMIC AGENTS, 15 February 2019 (2019-02-15) * |
| VERMA ET AL., SGLT2 INHIBITORS AND MECHANISMS OF CARDIOVASCULAR BENEFIT, 22 August 2018 (2018-08-22) * |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI867086B (zh) | 2024-12-21 |
| CN114650824A (zh) | 2022-06-21 |
| US12551484B2 (en) | 2026-02-17 |
| EP4054584A4 (en) | 2023-11-08 |
| MX2022005029A (es) | 2022-07-12 |
| TW202131924A (zh) | 2021-09-01 |
| KR20220098757A (ko) | 2022-07-12 |
| CA3160147A1 (en) | 2021-05-14 |
| IL292696B1 (en) | 2026-01-01 |
| KR102935008B1 (ko) | 2026-03-09 |
| EP4054584A1 (en) | 2022-09-14 |
| JP7502811B2 (ja) | 2024-06-19 |
| IL292696A (en) | 2022-07-01 |
| US20220370452A1 (en) | 2022-11-24 |
| ES3042146T3 (en) | 2025-11-18 |
| DK4054584T3 (en) | 2025-09-01 |
| FI4054584T3 (fi) | 2025-08-22 |
| HUE073043T2 (hu) | 2025-12-28 |
| AU2020377539A1 (en) | 2022-05-19 |
| JP2023500685A (ja) | 2023-01-10 |
| BR112022008223A2 (pt) | 2022-09-06 |
| PL4054584T3 (pl) | 2025-11-03 |
| EP4054584B1 (en) | 2025-07-09 |
| PT4054584T (pt) | 2025-07-16 |
| WO2021090061A1 (en) | 2021-05-14 |
| AU2020377539B2 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4054584T3 (en) | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | |
| RS67775B1 (sr) | Kombinovana terapija koja uključuje inhibitor kras-g12c i jedan ili više dodatnih farmaceutski aktivnih agenasa za lečenje kancera | |
| IL283598A (en) | Combined treatment with radio-immune conjugates and a checkpoint inhibitor | |
| IL320829B2 (en) | PARP1 inhibitors and their uses | |
| IL280591A (en) | Methods for delaying the onset of new type 2 diabetes and slowing the progression and treatment of type 2 diabetes | |
| PL4094763T3 (pl) | Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem | |
| GB202204420D0 (en) | Crypto-erasure via internal and/or external action | |
| IL275925A (en) | Prevention and treatment of organ damage | |
| ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
| IL294344B1 (en) | Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor | |
| IL321017A (en) | Inhibitors and/or decomposers containing 3-fluoro-4-hydroxybenzmide and uses thereof | |
| IL309243A (en) | Radioimmunoconjugates and combination therapy with barrier surveillance | |
| GB202103578D0 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| PL4069278T3 (pl) | Sposoby i kompozycje do zapobiegania cukrzycy typu 1 | |
| HK40076178A (en) | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor | |
| EP4178359A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS | |
| HUE059233T2 (hu) | Vegyület epizootius nyúl-enteropátia kezelésében és/vagy megelõzésében való alkalmazásra | |
| PL4061399T3 (pl) | Działanie insulinotropowe i glukagonotropowe beta-laktoglobuliny | |
| GB202218617D0 (en) | Triggered-producer and triggered-consumer instructions | |
| GB202210704D0 (en) | Biofilm prevention and treatment | |
| AU2025203707A1 (en) | Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome | |
| HK40087806A (en) | Combination therapies for the treatment and prevention of biofilms | |
| CA3278912A1 (en) | Raf inhibitor and kras g12c inhibitor combination therapy | |
| GB202114665D0 (en) | Addition and subtraction board | |
| GB201907609D0 (en) | Treatment and prevention of malaria |